574729-25-2

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 3-amino-5-nitro-1H-indazole-1-carboxylate is used as a building block in organic synthesis for the development of pharmaceuticals. Its unique structure and functional groups contribute to the creation of new drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, tert-Butyl 3-amino-5-nitro-1H-indazole-1-carboxylate serves as a key intermediate in the synthesis of various agrochemicals. Its incorporation into these products can lead to the development of innovative solutions for crop protection and enhancement of agricultural yields.
Safety Precautions:
Given the nature of tert-Butyl 3-amino-5-nitro-1H-indazole-1-carboxylate as a chemical compound, it is essential to follow proper handling procedures and safety precautions to minimize the risk of exposure. This includes the use of personal protective equipment, working in well-ventilated areas, and adhering to guidelines for chemical storage and disposal.

Upstream product

• 41339-17-7 5-nitro-1H-indazol-3-amine 
• 34619-03-9 tert-butyldicarbonate 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 
• 17417-09-3 2-fluoro-5-nitrobenzonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1268262-09-4 C₂₀H₂₀N₄O₆ 
• 1094505-69-7 tert-butyl 3-(benzoyl-amino)-5-nitroindazole-1-carboxylate 
• 574729-26-3 tert-butyl 3,5-diamino-1H-indazole-1-carboxylate 
• 574729-28-5 3-(3-Chlorobenzoylamino)-5-nitroindazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele

RAS mutations are found in 30% of all human cancers, with KRAS the most frequently mutated among the three RAS isoforms (KRAS, NRAS, and HRAS). However, directly targeting oncogenic KRAS with small molecules in the nucleotide-binding site has been difficult because of the high affinity of KRAS for GDP and GTP. We designed an engineered allele of KRAS and a covalent inhibitor that competes for GTP and GDP. This ligand-receptor combination demonstrates that the high affinity of GTP and GDP for RAS proteins can be overcome with a covalent inhibitor and a suitably engineered binding site. The covalent inhibitor irreversibly modifies the protein at the engineered nucleotide-binding site and is able to compete with GDP and GTP. This provides a new tool for studying KRAS function and suggests strategies for targeting the nucleotide-binding site of oncogenic RAS proteins.

In Silico HTS and Structure Based Optimization of Indazole-Derived ULK1 Inhibitors

We present the outcome of an in silico high throughput screen (HTS) and optimization of a small molecule Unc-51-Like Kinase 1 (ULK1) inhibitor hit, SR-17398, with an indazole core. Docking studies guided design efforts that led to inhibitors with increase

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Protein kinase affinity reagents based on a 5-aminoindazole scaffold

Affinity reagents that target protein kinases are powerful tools for signal transduction research. Here, we describe a general set of kinase ligands based on a 5-aminoindazole scaffold. This scaffold can readily be derivatized with diverse binding elements and immobilized analogs allow selective enrichment of protein kinases from complex mixtures.

Indazole compounds useful as protein kinase inhibitors

The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.